The Effect of Supratentorial Grade II Gliomas Growth Rate on their Prognosis

Česká verzia

Authors: M. Fabian ^1,2; M. Jezberová ²; Ľ. Pružincová ²; V. Belan ²; M. Chorvath ³; B. Rychlý ⁴; P. Kalina ⁵; J. Šteňo ⁶; A. Šteňo ⁶
Authors place of work: Rádiodiagnostická klinika LF UK a UN Bratislava ¹; Dr. Magnet s. r. o., pracovisko Kramáre, Bratislava ²; Klinika stereotaktickej rádiochirurgie OÚSA a VŠZASP, Bratislava ³; Cytopathos s. r. o., Bratislava ⁴; II. Neurologická klinika LF UK a UN Bratislava ⁵; Neurochirurgická klinika LF UK a UN Bratislava ⁶
Published in the journal: Cesk Slov Neurol N 2015; 78/111(3): 274-281
Category: Review Article

Summary

The impact of growth rate of supratentorial infiltrative grade II gliomas on their prognosis has been shown to be highly significant. This is probably one of the most important prognostic markers predicting a risk of early malignant transformation. The aim of this summary report is to describe current knowledge concerning the impact of growth rate of untreated grade II gliomas on their prognosis as well as to describe the options for growth rates quantification.

Key words:
low-grade glioma – growth rate – prognosis – malignant transformation

The authors declare they have no potential conflicts of interest concerning drugs, products, or services used in the study.

The Editorial Board declares that the manuscript met the ICMJE “uniform requirements” for biomedical papers.

Zdroje

1. Šteňo A, Belan V, Kalina P, Fabian M, Šteňo J. Vplyv chirurgickej liečby na prognózu dospelých pacientov so supratentoriálnymi low‑ grade gliómami. Cesk Slov Neurol N 2011; 74/ 107(3): 273– 278.

2. Pouratian N, Schiff D. Management of low‑ grade glioma. Curr Neurol Neurosci Rep 2010; 10(3): 224– 231. doi: 10.1007/ s11910‑ 010‑ 0105‑ 7.

3. Soffieti R, Baumert BG, Bello L, von Deimling A, Duffau H, Frénay M et al. Guidelines on management of low‑ grade gliomas: report of an EFNS‑ EANO Task Force. Eur J Neurol 2010; 17(9): 1124– 1133. doi: 10.1111/ j.1468‑ 1331.2010.03151.x.

4. Potts MB, Smith JS, Molinaro AM, Berger MS. Natural history and surgical management of incidentally discovered low‑ grade gliomas. J Neurosurg 2012; 116(2): 365– 372. doi: 10.3171/ 2011.9.JNS111068.

5. Pallud J, Capelle L, Mandonnet E. Comment on parameters of low‑ grade glioma as predictors. Radiology 2010; 256(3): 1014. doi: 10.1148/ radiol.100299.

6. Perry A. Pathology of low‑ grade gliomas: an update of emerging concepts. Neuro Oncol 2003; 5(3): 168– 178.

7. Schiffbauer H, Ferari P, Rowley HA, Berger MS, Roberts TP. Functional activity within brain tumors: a magnetic source imaging study. Neurosurgery 2001; 49(6): 1313– 1320.

8. Mandonnet E, Pallud J, Fontaine D, Taillander L, Bauchet L, Peruzzi P et al. Inter‑ and intrapatients comparison of WHO grade II glioma kinetics before and after surgical resection. Neurosurg Rev 2010; 33(1): 91– 96. doi: 10.1007/ s10143‑ 009‑ 0229‑ x.

9. Afra D, Osztie E, Sipos L, Vitanovics D. Preoperative history and postoperative survival of supratentorial low‑ grade astrocytomas. Br J Neurosurg Rev 1999; 13(3): 299– 305.

10. Whittle IR. The dilemma of low-grade glioma. J Neurol Neurosurg Psychiatry 2004; 75 (Suppl 2): ii31– ii36.

11. Frazier JL, Johnson MW, Burger PC, Weingart JD, Quinones‑ Hinojosa A. Rapid malignant transformation of low‑ grade astrocytomas: report of 2 cases and review of the literature. World Neurosurg 2010; 73(1): 53– 62. doi: 10.1016/ j.surneu.2009.05.010.

12. Pignatti F, van den Bent M, Curran D, Debruyne C, Sylvester R, Therasse P et al. Prognostic factors for survival in adult patients with cerebral low‑ grade glioma. J Clin Oncol 2002; 20(8): 2076– 2084.

13. Chang EF, Smith JS, Chang SM, Lamborn KR, Prados MD,Butowski N et al. Preoperative prognostic classification system for hemispheric low‑ grade gliomas in adults. J Neurosurg 2008; 109(5): 817– 824. doi: 10.3171/ JNS/ 2008/ 109/ 11/ 0817.

14. Houillier C, Mohktari K, Carpentier C, Criniere E, Marie Y,Rousseau A. Chromosome 9p and 10q losses predict outcome in low‑ grade gliomas. Neuro Oncol 2010; 12(1): 2– 6. doi: 10.1093/ neuonc/ nop002.

15. Chen R, Ravindra VM, Cohen AL, Jensen RL, Salzman KL, Prescot AP et al. Molecular features assisting in diagnosis, surgery, and treatment decision making in low‑ grade gliomas. Neurosurg Focus 2015; 38(3): E2. doi:10.3171/ 2015.1.FOCUS14745.

16. Wang JB, Dong DF, Wang MD, Gao K. IDH1 overexpression induced chemotherapy resistance and IDH1 mutation enhanced chemotherapy sensitivity in Glioma cells in vitro and in vivo. Asian Pac J Cancer Prev 2014; 15(1): 427– 432.

17. McGirt MJ, Chaichana KL, Attenello FJ, Weingart JD,Than K, Burger PC et al. Extent of surgical resection is independently associated with survival in patients with hemispheric infiltrating low‑ grade gliomas. Neurosurgery 2008; 63(4): 700– 707. doi: 10.1227/ 01.NEU.0000325729.41085.73.

18. Ahmadi R, Dictus C, Hartmann C, Zurn O, Edler L, Hartmann M. Long‑term outcome and survival of surgically treated supratentorial low‑ grade glioma in adult patients. Acta Neurochir (Wien) 2009; 151(11): 1359– 1365. doi: 10.1007/ s00701‑ 009‑ 0435‑ x.

19. Smith JS, Chang EF, Lamborn KR, Chang SM, Prados MD, Cha S et al. Role of extent of resection in the long‑term outcome of low‑ grade hemispheric gliomas. J Clin Oncol 2008; 26(8): 1338– 1345. doi: 10.1200/ JCO.2007.13.9337.

20. Claus EB, Horlacher A, Hsu L, Schwartz RB, Dello‑ Lacono D, Talos F et al. Survival rates in patients with low‑ grade glioma after intraoperative magnetic resonance image guidance. Cancer 2005; 103(6): 1227– 1233.

21. Duffau H, Lopes M, Arthuis F, Bitar A, Sichez JP, Van Effentere R et al. Contribution of intraoperative electrical stimulation in surgery of low‑ grade gliomas: a comparative study between two series without (1985– 1996) a and with (1996– 2003) functional mapping in the same institution. J Neurol Neurosurg Psychiatry 2005; 76: 845– 851.

22. Jakola AS, Myrmel KS, Kloster R, Torp SH, Lindal S, Unsgard G et al. Comparison of a strategy favoring early surgical resection vs a strategy favoring watchful waiting in low‑ grade gliomas. JAMA 2012; 308(18): 1881– 1888.

23. Sanai N, Berger MS. Glioma extent of resection and its impact on patient outcome. Neurosurgery 2008; 62(4): 753– 764. doi: 10.1227/ 01.neu.0000318159.21731.cf.

24. Riva M, Bello L. Low‑ grade glioma management: a contemporary surgical approach. Curr Opin Oncol 2014; 26(6): 615– 621. doi: 10.1097/ CCO.0000000000000120.

25. Chaichana KL, McGirt MJ, Laterra J, Olivi A, Quinones‑ Hinosaja A. Recurrence and malignant degeneration after resection of adult hemispheric low‑ grade gliomas. J Neurosurg 2010; 112(1): 10– 17. doi: 10.3171/ 2008.10.JNS08608.

26. Martino J, Taillandier L, Gasser SM, Peggy G, Duffau H. Re‑ operation is a safe and effective therapeutic strategy in reccurent WHO grade II gliomas within eloquent areas. Acta Neurochir 2009; 151(5): 427– 436. doi: 10.1007/ s00701‑ 009‑ 0232‑ 6.

27. Rees J, Watt H, Jager HR, Benton C, Tozer D, Tofts Pet al. Volumes and growth rates of untreated adult low‑ grade gliomas indicate risk of early malignant transformation. Eur J Radiol 2009; 72(1): 54– 64. doi: 10.1016/ j.ejrad.2008.06.013.

28. Brasil Caseiras G, Ciccarelli O, Altmann DR, Benton CE,Tozer DJ, Tofts PS et al. Low‑ grade gliomas: six month tumor growth predicts patient outcome better than admission tumor volume, relative cerebral blood volume, and apparent diffusion coefficient. Radiology 2009; 253(2): 505– 512. doi: 10.1148/ radiol.2532081623.

29. Hlaihel C, Guilloton L, Guyotat J, Streichenberger N, Honnorat J, Cotton F. Predictive value of multimodality MR using conventional, perfusion, and spectroscopy MRI in anaplastic transformation of low‑ grade oligodendrogliomas. J Neuro‑Oncol 2010; 97(1): 73– 80. doi: 10.1007/ s11060‑ 009‑ 9991‑ 4.

30. Pallud J, Blonski M, Mandonnet E, Audureau E, Fontaine D, Sanai N et al. Velocity of tumor spontaneous expansion predicts long‑term outcomes for diffuse low‑ grade gliomas. Neuro Oncol 2013; 15(5): 595– 606. doi: 10.1093/ neuonc/ nos331.

31. Rychlý B, Fabian M. Oligodendrogliové tumory: histologicko‑rádiologické korelácie. Lek Obzor 2010; 5(59): 203– 204.

32. Bynevelt M, Britton J, Seymour H, MacSweeney E, Tomas N, Sandhu K. Flair imaging in the follow‑up of low‑ grade gliomas: time to dispense with the dual echo? Neuroradiology 2001; 43(2): 129– 133.

33. Pallud J, Varlet P, Devaux B, Geha S, Badouval M, Deroulers C et al. Diffuse low‑ grade oligodendrogliomas extend beyond MRI‑ defined abnormalities. Neurology 2010; 74(21): 1724– 1731. doi: 10.1212/ WNL.0b013e3181e04264.

34. Scott JN, Brasher PM, Sevick RJ, Rewcastle NB, Forsyth PA. How often are nonenhancing supratentorial gliomas malignant? A population study. Neurology 2002; 59(6): 947– 949.

35. While ML, Zhang Y, Kirby P, Ryken TC. Can tumor contrast enhancement be used as a criterion for differentiating tumor grades of oligodendrogliomas? AJNR Am J Neuroradiol 2005; 26(4): 784– 790.

36. Belan V, Pružincová Ľ, Srbecký M. MR v diagnostike a liečbe primárnych nádorov mozgu. Onkológia (Bratisl) 2010; 5(3): 138– 141.

37. Pročka V, Makaiova I, Šteňo J, Kalina P, Belan V, Pružincová Ľ et al. Skúsenosti s využitím 18FDG PET v diferenciálnej diagnostike low‑ grade a highgrade gliomov. Onkologia (Bratisl) 2010; 5(3): 156– 116.

38. Widhalm G, Wolfsberger S, Minchev G, Woehrer A, Krssak M, Czech T et al. 5– Aminolevulinic acid is a promising marker for detection of anaplastic foci in diffusely infiltrating gliomas with nonsignificant contrast enhancement. Cancer 2010; 116(6): 1545– 1552. doi: 10.1002/ cncr.24903.

39. Pallud J, Taillandier L, Capelle L, Fontaine D, Peyre M,Ducray F et al. Quantitative morphological magnetic resonance imaging follow‑up of low‑ grade glioma: a plead for systematic measurement of growth rates. Neurosurgery 2012; 71(3): 729– 739.

40. Mandonnet E, Pallud J, Clatz O, Taillander L, Konukoglu E, Duffau H et al. Computational modeling of the WHO grade II glioma dynamics: principles and applications to management paradigm. Neurosurg Rev 2008; 31(3): 263– 269. doi: 10.1007/ s10143‑ 008‑ 0128‑ 6.

41. Mandonnet E, Delattre JY, Tanguy ML, Swanson KR, Carpentier AF, Duffau H et al. Continuous growth of mean tumor diameter in a subset of grade II gliomas. Ann Neurol 2003; 53(4): 524– 528.

42. Ricard D, Kaloshi G, Amiel‑ Benouaich A, Lejeune J, Marie Y, Mandonnet E et al. Dynamic history of low‑ grade gliomas before and after temozolomide treatment. Ann Neurol 2007; 61(5): 484– 490.

43. Woodward DE, Cook J, Tracqui P, Cruywagen GC, Murray JD, Alvord EC jr et al. A mathematical model of glioma growth: the effect of extent of surgical resection. Cell Prolif 1996; 29(6): 269– 288.

44. Swanson KR, Alvord EC jr, Murray JD. A quantitative model for differential motility of gliomas in grey and white matter. Cell Prolif 2000; 33(5): 317– 329.

45. Schmitt P, Mandonnet E, Perdreau A, Angelini ED. Effect of slice thickness and head rotation when measuring glioma sizes on MRI: in support of volume segmentation versus two largest diameters methods. J Neurooncol 2013; 112(2): 165– 172. doi: 10.1007/ s11060‑ 013‑ 1051‑ 4.

46. Sorensen AG, Patel S, Harmath C, Bridges S, Synnott J,Sievers A et al. Comparison of diameter and perimeter methods for tumor volume calculation. J Clin Oncol 2001; 19(2): 551– 557.

47. Jakola AS, Moen KG, Ole S, Kvistad KA. “No growth” on serial MRI scans of a low-grade glioma? Acta Neurochirurgica 2013; 155(23): 2243– 2244. doi: 10.1007/ s00701‑ 013‑ 1914‑ 7.

48. Pallud J, Mandonnet E, Duffau H, Kujas M, Guillevin R,Galanaud D et al. Prognostic value of initial magnetic resonance imaging growth rates for World Health Organization grade II gliomas. Ann Neurol 2006; 60(3): 380– 383.

49. Chang EF, Clark A, Jensen RL, Bernstein M, Guha A, Carrabba G et al. Multiinstitutional validation of the University of California at San Francisco Low‑ grade Glioma Prognostic Scoring System. Clinical article. J Neurosurg 2009; 111(2): 203– 210.